Innovation & intellectual property · 22/05/1996
Notice of Two Year Exclusivity Period for DAYPRO Oxaprozin
The U.S. Patent and Trademark Office has received a notification from G. D. Searle & Co. regarding its claim of entitlement under the FDA Export Reform and Enhancement Act of 1996, which grants a two-year exclusivity period for the DAYPRO oxaprozin drug product.
Original source language: Federal Register — Patent and Trademark OfficeOpen original release →